WHO Sounds Alert Over Critical Scarcity of Weight-Loss Medications
Less than a tenth of patients who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it publishes its first guidance on the drugs.
With more than one billion individuals worldwide now obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidance acknowledges that excess weight is a lifelong illness that can be managed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key hurdles to widespread access to the injections that can aid individuals in losing substantial weight, notes the organization.
GLP-1 Therapy Scarcity
Even under the current best projected outlook, the supply of such drugs would only suffice for about 100 million people – less than 10% of the global need, as stated by the health organization.
The advice encourages countries and companies to widen availability, through measures including licensing agreements.
Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Injections Operate
The injections imitate a natural hormone to slow digestion, reduce hunger and increase the sense of being full so individuals reduce food intake.
Individuals typically start to lose weight within a few weeks of beginning the once-weekly jabs.
Research suggests patients may see weight return within a year of halting the treatment, as their typical food cravings return.
To be overweight or obese elevates your likelihood for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight affects people in every country and was linked to millions of fatalities worldwide in 2024, according to the health agency.
